[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9Gd5rVtlWj_DPTYMsdZUbKvn7i8PCS_C2UCBVxcBams":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":83,"rows":90},"Haukeland University Hospital",[4],279,false,80,15,93959,34,221,[14,17,19,21,24,26,28,30],{"name":15,"count":16},"Ischemic Stroke",5,{"name":18,"count":16},"Obesity",{"name":20,"count":16},"Amyotrophic Lateral Sclerosis",{"name":22,"count":23},"Anxiety",4,{"name":25,"count":23},"Quality of Life",{"name":27,"count":23},"Cognitive Impairment",{"name":29,"count":23},"Health Literacy",{"name":31,"count":23},"Physical Activity",[33,38,43,48,53,58,63,68,73,78],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT02624973","PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","2020-06-01","Neoadjuvant tamoxifen + goserelin",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02543710","Biomarker Guided Treatment in Gynaecological Cancer","2020-12","Biomarker guided weekly taxane treatment in endometrial\u002F ovarian cancer",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05290025","Easy Access to Smoking Cessation for People Receiving Opioid Agonist Therapy Who Are Smoking Tobacco","2023-10-31","Nicotine patch",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT02965950","The p53 Breast Cancer Trial","2024-05","Cyclophosphamide",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04749667","Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis","2025-03-24","Saline",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04578639","Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease","2025-08-14","Rituximab",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05852873","PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway","2025-09-09","Nirmatrelvir\u002Fritonavir",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06199557","A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML\u002FHR-MDS Patients","2025-11-30","Hydroxyurea, Hydroxycarbamide",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03477500","Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","2026-11-21","Cyclophosphamide and ATG",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT07042672","Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","2027-11-05","GLP-1",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,116,151,210,234,252,270,288,314,361,388,406,441,459,477,495,513,531,549,567,585,603,621,639,657,675,700,718,736,762,788,813,831,849,874,920,947,965,983,1009,1034,1070,1092,1120,1138,1163,1187,1211,1240,1258,1282,1317,1355,1380,1398,1422,1449,1467,1485,1512,1530,1548,1566,1584,1602,1620,1646,1670,1695,1713,1739,1762,1789,1815,1840,1868,1886,1904,1922,1947,1971,1995,2020,2047,2065,2083,2111,2136],{"intervention":42,"totalTrials":92,"cells":93},1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":114},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":41},[105],{"nctId":39,"briefTitle":40,"status":106,"phases":107,"primaryCompletion":41,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"RECRUITING",[88],"2033-12","2015-10",1300,[112],"Endometrial Cancer",[42],{"trials":115,"activeCount":96},[],{"intervention":117,"totalTrials":118,"cells":119},"Ocrelizumab",2,{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":147,"NA":149},{"trials":121,"activeCount":96},[],{"trials":123,"activeCount":96},[],{"trials":125,"activeCount":96},[],{"trials":127,"activeCount":118,"soonestReadout":61},[128,139],{"nctId":74,"briefTitle":75,"status":129,"phases":130,"primaryCompletion":76,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"ACTIVE_NOT_RECRUITING",[87],"2028-03-21","2018-03-21",100,[135],"Multiple Sclerosis",[77,137,138,117],"Alemtuzumab","Cladribine Pill",{"nctId":59,"briefTitle":60,"status":129,"phases":140,"primaryCompletion":61,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},[87],"2025-09-14","2020-11-02",214,[145],"Relapsing Remitting Multiple Sclerosis",[62,117],{"trials":148,"activeCount":96},[],{"trials":150,"activeCount":96},[],{"intervention":62,"totalTrials":16,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":181,"PHASE4":206,"NA":208},{"trials":154,"activeCount":96},[],{"trials":156,"activeCount":96},[],{"trials":158,"activeCount":96},[159,171],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":170},"NCT01156909","B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome","COMPLETED",[86],"2014-02","2010-10",29,[168,169],"Chronic Fatigue Syndrome","Myalgic Encephalomyelitis",[62],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":180},"NCT01156922","B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome","TERMINATED",[86],"2016-04","2010-06",8,[168,169],[62],{"trials":182,"activeCount":92,"soonestReadout":61},[183,194,198],{"nctId":184,"briefTitle":185,"status":162,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT02229942","B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome\u002F Myalgic Encephalopathy (CFS\u002FME). A Randomized Phase-III Study.",[87],"2017-09","2017-11","2014-09",151,[192],"Chronic Fatigue Syndrome\u002F Myalgic Encephalitis (CFS\u002FME)",[62],{"nctId":59,"briefTitle":60,"status":129,"phases":195,"primaryCompletion":61,"completion":141,"start":142,"enrollment":143,"conditions":196,"interventions":197},[87],[145],[62,117],{"nctId":199,"briefTitle":200,"status":162,"phases":201,"primaryCompletion":177,"completion":177,"start":202,"enrollment":203,"conditions":204,"interventions":205},"NCT00848692","Drug Intervention in Chronic Fatigue Syndrome",[86,87],"2008-06",30,[168],[62,57],{"trials":207,"activeCount":96},[],{"trials":209,"activeCount":96},[],{"intervention":67,"totalTrials":92,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":230,"NA":232},{"trials":213,"activeCount":96},[],{"trials":215,"activeCount":96},[],{"trials":217,"activeCount":96},[],{"trials":219,"activeCount":92,"soonestReadout":66},[220],{"nctId":64,"briefTitle":65,"status":129,"phases":221,"primaryCompletion":66,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":229},[87],"2027-06-11","2023-05-12",2000,[226,227,228],"Post COVID-19 Condition, Unspecified","SARS-CoV2 Infection","COVID-19",[67],{"trials":231,"activeCount":96},[],{"trials":233,"activeCount":96},[],{"intervention":77,"totalTrials":92,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":248,"NA":250},{"trials":237,"activeCount":96},[],{"trials":239,"activeCount":96},[],{"trials":241,"activeCount":96},[],{"trials":243,"activeCount":92,"soonestReadout":76},[244],{"nctId":74,"briefTitle":75,"status":129,"phases":245,"primaryCompletion":76,"completion":131,"start":132,"enrollment":133,"conditions":246,"interventions":247},[87],[135],[77,137,138,117],{"trials":249,"activeCount":96},[],{"trials":251,"activeCount":96},[],{"intervention":137,"totalTrials":92,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":266,"NA":268},{"trials":255,"activeCount":96},[],{"trials":257,"activeCount":96},[],{"trials":259,"activeCount":96},[],{"trials":261,"activeCount":92,"soonestReadout":76},[262],{"nctId":74,"briefTitle":75,"status":129,"phases":263,"primaryCompletion":76,"completion":131,"start":132,"enrollment":133,"conditions":264,"interventions":265},[87],[135],[77,137,138,117],{"trials":267,"activeCount":96},[],{"trials":269,"activeCount":96},[],{"intervention":138,"totalTrials":92,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":284,"NA":286},{"trials":273,"activeCount":96},[],{"trials":275,"activeCount":96},[],{"trials":277,"activeCount":96},[],{"trials":279,"activeCount":92,"soonestReadout":76},[280],{"nctId":74,"briefTitle":75,"status":129,"phases":281,"primaryCompletion":76,"completion":131,"start":132,"enrollment":133,"conditions":282,"interventions":283},[87],[135],[77,137,138,117],{"trials":285,"activeCount":96},[],{"trials":287,"activeCount":96},[],{"intervention":57,"totalTrials":118,"cells":289},{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":304,"PHASE4":310,"NA":312},{"trials":291,"activeCount":96},[],{"trials":293,"activeCount":96},[],{"trials":295,"activeCount":92,"soonestReadout":56},[296],{"nctId":54,"briefTitle":55,"status":129,"phases":297,"primaryCompletion":56,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},[85,86],"2027-03-15","2021-08-09",18,[135,302],"Progressive Multiple Sclerosis",[57],{"trials":305,"activeCount":96},[306],{"nctId":199,"briefTitle":200,"status":162,"phases":307,"primaryCompletion":177,"completion":177,"start":202,"enrollment":203,"conditions":308,"interventions":309},[86,87],[168],[62,57],{"trials":311,"activeCount":96},[],{"trials":313,"activeCount":96},[],{"intervention":52,"totalTrials":315,"cells":316},3,{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":318,"activeCount":96},[],{"trials":320,"activeCount":96},[],{"trials":322,"activeCount":92,"soonestReadout":51},[323,335,344],{"nctId":324,"briefTitle":325,"status":174,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":334},"NCT03149679","The p53 Colorectal Cancer Trial",[86],"2020-08-07","2017-05-09",12,[331,332,333],"Colorectal Cancer Metastatic","Colorectal Cancer Stage IV","TP53 Gene Mutation",[52],{"nctId":49,"briefTitle":50,"status":129,"phases":336,"primaryCompletion":51,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":343},[86],"2033-05","2016-10",190,[341,342],"Locally Advanced Breast Cancer","Metastatic Breast Carcinoma",[52],{"nctId":345,"briefTitle":346,"status":162,"phases":347,"primaryCompletion":348,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":354},"NCT02444091","Cyclophosphamide in Myalgic Encephalopathy\u002F Chronic Fatigue Syndrome (ME\u002FCFS)",[86],"2019-12-06","2015-03",40,[352,353],"Chronic Fatigue Syndrome (CFS)","Myalgic Encephalomyelitis (ME)",[52],{"trials":356,"activeCount":96},[],{"trials":358,"activeCount":96},[],{"trials":360,"activeCount":96},[],{"intervention":362,"totalTrials":92,"cells":363},"Sirolimus 1 mg Oral",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":382,"PHASE4":384,"NA":386},{"trials":365,"activeCount":96},[],{"trials":367,"activeCount":96},[],{"trials":369,"activeCount":92,"soonestReadout":374},[370],{"nctId":371,"briefTitle":372,"status":106,"phases":373,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":380},"NCT04936854","Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease",[86],"2028-01","2028-12","2023-01-01",60,[379],"Thyroid-Associated Ophthalmopathy",[362,381],"Methylprednisolone",{"trials":383,"activeCount":96},[],{"trials":385,"activeCount":96},[],{"trials":387,"activeCount":96},[],{"intervention":381,"totalTrials":92,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":400,"PHASE4":402,"NA":404},{"trials":391,"activeCount":96},[],{"trials":393,"activeCount":96},[],{"trials":395,"activeCount":92,"soonestReadout":374},[396],{"nctId":371,"briefTitle":372,"status":106,"phases":397,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":398,"interventions":399},[86],[379],[362,381],{"trials":401,"activeCount":96},[],{"trials":403,"activeCount":96},[],{"trials":405,"activeCount":96},[],{"intervention":37,"totalTrials":92,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":435,"PHASE4":437,"NA":439},{"trials":409,"activeCount":96},[],{"trials":411,"activeCount":96},[],{"trials":413,"activeCount":92,"soonestReadout":36},[414],{"nctId":34,"briefTitle":35,"status":129,"phases":415,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":421},[86],"2030-06","2016-04-15",200,[420],"Breast Cancer",[37,422,423,424,425,426,427,428,429,430,431,432,433,434],"Neoadjuvant letrozole","Neoadjuvant endocrine therapy + palbociclib","Neoadjuvant docetaxel + cyclophosphamide","Neoadjuvant docetaxel","Neoadjuvant docetaxel + trastuzumab + pertuzumab","Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab","Neoadjuvant olaparib","Neoadjuvant cyclophosphamide","Adjuvant trastuzumab","Adjuvant letrozole","Adjuvant tamoxifen + goserelin","Adjuvant palbociclib","Adjuvant Epirubicin+ Cyclophosphamide",{"trials":436,"activeCount":96},[],{"trials":438,"activeCount":96},[],{"trials":440,"activeCount":96},[],{"intervention":422,"totalTrials":92,"cells":442},{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":444,"activeCount":96},[],{"trials":446,"activeCount":96},[],{"trials":448,"activeCount":92,"soonestReadout":36},[449],{"nctId":34,"briefTitle":35,"status":129,"phases":450,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":451,"interventions":452},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":454,"activeCount":96},[],{"trials":456,"activeCount":96},[],{"trials":458,"activeCount":96},[],{"intervention":423,"totalTrials":92,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":471,"PHASE4":473,"NA":475},{"trials":462,"activeCount":96},[],{"trials":464,"activeCount":96},[],{"trials":466,"activeCount":92,"soonestReadout":36},[467],{"nctId":34,"briefTitle":35,"status":129,"phases":468,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":469,"interventions":470},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":472,"activeCount":96},[],{"trials":474,"activeCount":96},[],{"trials":476,"activeCount":96},[],{"intervention":424,"totalTrials":92,"cells":478},{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":489,"PHASE4":491,"NA":493},{"trials":480,"activeCount":96},[],{"trials":482,"activeCount":96},[],{"trials":484,"activeCount":92,"soonestReadout":36},[485],{"nctId":34,"briefTitle":35,"status":129,"phases":486,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":487,"interventions":488},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":490,"activeCount":96},[],{"trials":492,"activeCount":96},[],{"trials":494,"activeCount":96},[],{"intervention":425,"totalTrials":92,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":498,"activeCount":96},[],{"trials":500,"activeCount":96},[],{"trials":502,"activeCount":92,"soonestReadout":36},[503],{"nctId":34,"briefTitle":35,"status":129,"phases":504,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":505,"interventions":506},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":508,"activeCount":96},[],{"trials":510,"activeCount":96},[],{"trials":512,"activeCount":96},[],{"intervention":426,"totalTrials":92,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":516,"activeCount":96},[],{"trials":518,"activeCount":96},[],{"trials":520,"activeCount":92,"soonestReadout":36},[521],{"nctId":34,"briefTitle":35,"status":129,"phases":522,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":523,"interventions":524},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":526,"activeCount":96},[],{"trials":528,"activeCount":96},[],{"trials":530,"activeCount":96},[],{"intervention":427,"totalTrials":92,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":534,"activeCount":96},[],{"trials":536,"activeCount":96},[],{"trials":538,"activeCount":92,"soonestReadout":36},[539],{"nctId":34,"briefTitle":35,"status":129,"phases":540,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":541,"interventions":542},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":544,"activeCount":96},[],{"trials":546,"activeCount":96},[],{"trials":548,"activeCount":96},[],{"intervention":428,"totalTrials":92,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":552,"activeCount":96},[],{"trials":554,"activeCount":96},[],{"trials":556,"activeCount":92,"soonestReadout":36},[557],{"nctId":34,"briefTitle":35,"status":129,"phases":558,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":559,"interventions":560},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":562,"activeCount":96},[],{"trials":564,"activeCount":96},[],{"trials":566,"activeCount":96},[],{"intervention":429,"totalTrials":92,"cells":568},{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":573,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":570,"activeCount":96},[],{"trials":572,"activeCount":96},[],{"trials":574,"activeCount":92,"soonestReadout":36},[575],{"nctId":34,"briefTitle":35,"status":129,"phases":576,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":577,"interventions":578},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":580,"activeCount":96},[],{"trials":582,"activeCount":96},[],{"trials":584,"activeCount":96},[],{"intervention":430,"totalTrials":92,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":588,"activeCount":96},[],{"trials":590,"activeCount":96},[],{"trials":592,"activeCount":92,"soonestReadout":36},[593],{"nctId":34,"briefTitle":35,"status":129,"phases":594,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":595,"interventions":596},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":598,"activeCount":96},[],{"trials":600,"activeCount":96},[],{"trials":602,"activeCount":96},[],{"intervention":431,"totalTrials":92,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":615,"PHASE4":617,"NA":619},{"trials":606,"activeCount":96},[],{"trials":608,"activeCount":96},[],{"trials":610,"activeCount":92,"soonestReadout":36},[611],{"nctId":34,"briefTitle":35,"status":129,"phases":612,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":613,"interventions":614},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":616,"activeCount":96},[],{"trials":618,"activeCount":96},[],{"trials":620,"activeCount":96},[],{"intervention":432,"totalTrials":92,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":624,"activeCount":96},[],{"trials":626,"activeCount":96},[],{"trials":628,"activeCount":92,"soonestReadout":36},[629],{"nctId":34,"briefTitle":35,"status":129,"phases":630,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":631,"interventions":632},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":634,"activeCount":96},[],{"trials":636,"activeCount":96},[],{"trials":638,"activeCount":96},[],{"intervention":433,"totalTrials":92,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":642,"activeCount":96},[],{"trials":644,"activeCount":96},[],{"trials":646,"activeCount":92,"soonestReadout":36},[647],{"nctId":34,"briefTitle":35,"status":129,"phases":648,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":649,"interventions":650},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":652,"activeCount":96},[],{"trials":654,"activeCount":96},[],{"trials":656,"activeCount":96},[],{"intervention":434,"totalTrials":92,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":660,"activeCount":96},[],{"trials":662,"activeCount":96},[],{"trials":664,"activeCount":92,"soonestReadout":36},[665],{"nctId":34,"briefTitle":35,"status":129,"phases":666,"primaryCompletion":36,"completion":416,"start":417,"enrollment":418,"conditions":667,"interventions":668},[86],[420],[37,422,423,424,425,426,427,428,429,430,431,432,433,434],{"trials":670,"activeCount":96},[],{"trials":672,"activeCount":96},[],{"trials":674,"activeCount":96},[],{"intervention":72,"totalTrials":92,"cells":676},{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":678,"activeCount":96},[],{"trials":680,"activeCount":96},[],{"trials":682,"activeCount":92,"soonestReadout":71},[683],{"nctId":69,"briefTitle":70,"status":106,"phases":684,"primaryCompletion":71,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":691},[85,86],"2029-09-30","2024-05-23",48,[689,690],"Acute Myeloid Leukemia, Adult","Myelodysplastic Syndromes, Adult",[72,692,693],"Valproic acid","6-Mercaptopurine",{"trials":695,"activeCount":96},[],{"trials":697,"activeCount":96},[],{"trials":699,"activeCount":96},[],{"intervention":692,"totalTrials":92,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":712,"PHASE4":714,"NA":716},{"trials":703,"activeCount":96},[],{"trials":705,"activeCount":96},[],{"trials":707,"activeCount":92,"soonestReadout":71},[708],{"nctId":69,"briefTitle":70,"status":106,"phases":709,"primaryCompletion":71,"completion":685,"start":686,"enrollment":687,"conditions":710,"interventions":711},[85,86],[689,690],[72,692,693],{"trials":713,"activeCount":96},[],{"trials":715,"activeCount":96},[],{"trials":717,"activeCount":96},[],{"intervention":693,"totalTrials":92,"cells":719},{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":721,"activeCount":96},[],{"trials":723,"activeCount":96},[],{"trials":725,"activeCount":92,"soonestReadout":71},[726],{"nctId":69,"briefTitle":70,"status":106,"phases":727,"primaryCompletion":71,"completion":685,"start":686,"enrollment":687,"conditions":728,"interventions":729},[85,86],[689,690],[72,692,693],{"trials":731,"activeCount":96},[],{"trials":733,"activeCount":96},[],{"trials":735,"activeCount":96},[],{"intervention":737,"totalTrials":92,"cells":738},"Psychotherapy as usual combined with single dose normal gut microbiota",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":754,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":740,"activeCount":96},[],{"trials":742,"activeCount":92,"soonestReadout":748},[743],{"nctId":744,"briefTitle":745,"status":746,"phases":747,"primaryCompletion":748,"completion":375,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT07574892","Reestablishing Normal Gut-brain Interaction in Anorexia Nervose With Normal Gut Microbiota","NOT_YET_RECRUITING",[85],"2028-11","2026-06-01",36,[752],"Anorexia Nervosa",[737],{"trials":755,"activeCount":96},[],{"trials":757,"activeCount":96},[],{"trials":759,"activeCount":96},[],{"trials":761,"activeCount":96},[],{"intervention":82,"totalTrials":92,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":774},{"trials":765,"activeCount":96},[],{"trials":767,"activeCount":96},[],{"trials":769,"activeCount":96},[],{"trials":771,"activeCount":96},[],{"trials":773,"activeCount":96},[],{"trials":775,"activeCount":92,"soonestReadout":81},[776],{"nctId":79,"briefTitle":80,"status":106,"phases":777,"primaryCompletion":81,"completion":778,"start":779,"enrollment":8,"conditions":780,"interventions":787},[],"2028-12-31","2025-07-01",[781,782,783,784,82,785,786],"Binge Eating Disorder Associated With Obesity","Binge Eating Disorder","Eating Disorder Binge","Eating Disorders","CBT","Obesity &Amp; Overweight",[82],{"intervention":47,"totalTrials":92,"cells":789},{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":791,"activeCount":96},[],{"trials":793,"activeCount":96},[],{"trials":795,"activeCount":96},[],{"trials":797,"activeCount":96},[],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":92,"soonestReadout":46},[802],{"nctId":44,"briefTitle":45,"status":129,"phases":803,"primaryCompletion":46,"completion":804,"start":805,"enrollment":806,"conditions":807,"interventions":810},[89],"2026-12","2022-04-07",266,[808,809],"Smoking Cessation","Substance-Related Disorders",[47,811,812],"Nicotine gum","Nicotine lozenge",{"intervention":811,"totalTrials":92,"cells":814},{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[],{"trials":820,"activeCount":96},[],{"trials":822,"activeCount":96},[],{"trials":824,"activeCount":96},[],{"trials":826,"activeCount":92,"soonestReadout":46},[827],{"nctId":44,"briefTitle":45,"status":129,"phases":828,"primaryCompletion":46,"completion":804,"start":805,"enrollment":806,"conditions":829,"interventions":830},[89],[808,809],[47,811,812],{"intervention":812,"totalTrials":92,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":843},{"trials":834,"activeCount":96},[],{"trials":836,"activeCount":96},[],{"trials":838,"activeCount":96},[],{"trials":840,"activeCount":96},[],{"trials":842,"activeCount":96},[],{"trials":844,"activeCount":92,"soonestReadout":46},[845],{"nctId":44,"briefTitle":45,"status":129,"phases":846,"primaryCompletion":46,"completion":804,"start":805,"enrollment":806,"conditions":847,"interventions":848},[89],[808,809],[47,811,812],{"intervention":850,"totalTrials":92,"cells":851},"Comprehensive molecular profiling",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":853,"activeCount":96},[],{"trials":855,"activeCount":96},[],{"trials":857,"activeCount":96},[],{"trials":859,"activeCount":96},[],{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":92,"soonestReadout":868},[864],{"nctId":865,"briefTitle":866,"status":746,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT07366008","The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP)",[89],"2033-01","2026-01",350,[872],"Cancer of Unknown Primary Site",[850],{"intervention":875,"totalTrials":315,"cells":876},"Sulfonylurea",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":918},{"trials":878,"activeCount":96},[],{"trials":880,"activeCount":96},[],{"trials":882,"activeCount":96},[],{"trials":884,"activeCount":96},[],{"trials":886,"activeCount":96},[887,897,909],{"nctId":888,"briefTitle":889,"status":890,"phases":891,"primaryCompletion":892,"completion":892,"start":893,"enrollment":203,"conditions":894,"interventions":896},"NCT02624830","Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)","UNKNOWN",[88],"2020-02","2019-02-15",[895],"Permanent Neonatal Diabetes Mellitus",[875],{"nctId":898,"briefTitle":899,"status":890,"phases":900,"primaryCompletion":901,"completion":901,"start":902,"enrollment":203,"conditions":903,"interventions":908},"NCT04239586","Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes",[88],"2022-04","2017-04-18",[904,905,906,907],"Maturity-Onset Diabetes of the Young, Type 3","Maturity Onset Diabetes of the Young, Type 1","Childhood Diabetes Mellitus","Insulin-dependent Diabetes Mellitus",[875],{"nctId":910,"briefTitle":911,"status":162,"phases":912,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":917},"NCT02624817","Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes",[88],"2016-08","2015-12",90,[895],[875],{"trials":919,"activeCount":96},[],{"intervention":921,"totalTrials":92,"cells":922},"Amisulpride",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":931,"NA":945},{"trials":924,"activeCount":96},[],{"trials":926,"activeCount":96},[],{"trials":928,"activeCount":96},[],{"trials":930,"activeCount":96},[],{"trials":932,"activeCount":96},[933],{"nctId":934,"briefTitle":935,"status":162,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":190,"conditions":939,"interventions":942},"NCT01446328","Bergen Psychosis Project 2 - The Best Intro Study",[88],"2017-12","2011-10",[940,941],"Schizophrenia","Psychotic Disorders",[921,943,944],"Aripiprazole","Olanzapine",{"trials":946,"activeCount":96},[],{"intervention":943,"totalTrials":92,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":963},{"trials":950,"activeCount":96},[],{"trials":952,"activeCount":96},[],{"trials":954,"activeCount":96},[],{"trials":956,"activeCount":96},[],{"trials":958,"activeCount":96},[959],{"nctId":934,"briefTitle":935,"status":162,"phases":960,"primaryCompletion":937,"completion":937,"start":938,"enrollment":190,"conditions":961,"interventions":962},[88],[940,941],[921,943,944],{"trials":964,"activeCount":96},[],{"intervention":944,"totalTrials":92,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":981},{"trials":968,"activeCount":96},[],{"trials":970,"activeCount":96},[],{"trials":972,"activeCount":96},[],{"trials":974,"activeCount":96},[],{"trials":976,"activeCount":96},[977],{"nctId":934,"briefTitle":935,"status":162,"phases":978,"primaryCompletion":937,"completion":937,"start":938,"enrollment":190,"conditions":979,"interventions":980},[88],[940,941],[921,943,944],{"trials":982,"activeCount":96},[],{"intervention":984,"totalTrials":92,"cells":985},"D-Cycloserine",{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":992,"PHASE4":994,"NA":1007},{"trials":987,"activeCount":96},[],{"trials":989,"activeCount":96},[],{"trials":991,"activeCount":96},[],{"trials":993,"activeCount":96},[],{"trials":995,"activeCount":96},[996],{"nctId":997,"briefTitle":998,"status":162,"phases":999,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1006},"NCT02656342","Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients?",[88],"2018-09","2019-02","2015-11",163,[1005],"Obsessive-Compulsive Disorder",[984],{"trials":1008,"activeCount":96},[],{"intervention":1010,"totalTrials":92,"cells":1011},"Hypertonic saline",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1020,"NA":1032},{"trials":1013,"activeCount":96},[],{"trials":1015,"activeCount":96},[],{"trials":1017,"activeCount":96},[],{"trials":1019,"activeCount":96},[],{"trials":1021,"activeCount":96},[1022],{"nctId":1023,"briefTitle":1024,"status":162,"phases":1025,"primaryCompletion":1026,"completion":1026,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1031},"NCT00469716","Hypertonic Saline-hetastarch in Cardiac Surgery",[88],"2008-05","2007-04",50,[1030],"Postoperative Cardiorespiratory Failure",[1010],{"trials":1033,"activeCount":96},[],{"intervention":1035,"totalTrials":118,"cells":1036},"Solu-Cortef",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1054,"PHASE4":1066,"NA":1068},{"trials":1038,"activeCount":96},[],{"trials":1040,"activeCount":96},[],{"trials":1042,"activeCount":96},[1043],{"nctId":1044,"briefTitle":1045,"status":162,"phases":1046,"primaryCompletion":1047,"completion":937,"start":1048,"enrollment":178,"conditions":1049,"interventions":1052},"NCT02096510","Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia",[85,86],"2016-12","2014-03-27",[1050,1051],"Addison Disease","Adrenal Hyperplasia Congenital",[1035,1053],"Cortef",{"trials":1055,"activeCount":96},[1056],{"nctId":1057,"briefTitle":1058,"status":162,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT01063569","Glucocorticoid Treatment in Addison's Disease",[86,87],"2012-12","2010-02",33,[1064],"Addison's Disease",[1035,1053],{"trials":1067,"activeCount":96},[],{"trials":1069,"activeCount":96},[],{"intervention":1053,"totalTrials":118,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1082,"PHASE4":1088,"NA":1090},{"trials":1073,"activeCount":96},[],{"trials":1075,"activeCount":96},[],{"trials":1077,"activeCount":96},[1078],{"nctId":1044,"briefTitle":1045,"status":162,"phases":1079,"primaryCompletion":1047,"completion":937,"start":1048,"enrollment":178,"conditions":1080,"interventions":1081},[85,86],[1050,1051],[1035,1053],{"trials":1083,"activeCount":96},[1084],{"nctId":1057,"briefTitle":1058,"status":162,"phases":1085,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1086,"interventions":1087},[86,87],[1064],[1035,1053],{"trials":1089,"activeCount":96},[],{"trials":1091,"activeCount":96},[],{"intervention":1093,"totalTrials":92,"cells":1094},"Tenecteplase",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1116,"NA":1118},{"trials":1096,"activeCount":96},[],{"trials":1098,"activeCount":96},[],{"trials":1100,"activeCount":96},[],{"trials":1102,"activeCount":96},[1103],{"nctId":1104,"briefTitle":1105,"status":174,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1114},"NCT03854500","The Norwegian Tenecteplase Stroke Trial 2",[87],"2021-09-30","2021-12-31","2019-10-28",201,[1112,1113,15],"Stroke, Acute","Cerebrovascular Disorders",[1093,1115],"Alteplase",{"trials":1117,"activeCount":96},[],{"trials":1119,"activeCount":96},[],{"intervention":1115,"totalTrials":92,"cells":1121},{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1128,"PHASE4":1134,"NA":1136},{"trials":1123,"activeCount":96},[],{"trials":1125,"activeCount":96},[],{"trials":1127,"activeCount":96},[],{"trials":1129,"activeCount":96},[1130],{"nctId":1104,"briefTitle":1105,"status":174,"phases":1131,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":1110,"conditions":1132,"interventions":1133},[87],[1112,1113,15],[1093,1115],{"trials":1135,"activeCount":96},[],{"trials":1137,"activeCount":96},[],{"intervention":1139,"totalTrials":92,"cells":1140},"HyperHAES vs. RA-solution\u002FNaCl",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1159,"NA":1161},{"trials":1142,"activeCount":96},[],{"trials":1144,"activeCount":96},[],{"trials":1146,"activeCount":96},[],{"trials":1148,"activeCount":96},[1149],{"nctId":1150,"briefTitle":1151,"status":162,"phases":1152,"primaryCompletion":1027,"completion":1153,"start":1154,"enrollment":1155,"conditions":1156,"interventions":1158},"NCT00347477","Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest",[87],"2009-03","2005-09",23,[1157],"Cardiac Arrest",[1139],{"trials":1160,"activeCount":96},[],{"trials":1162,"activeCount":96},[],{"intervention":1164,"totalTrials":92,"cells":1165},"Triomar™",{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1183,"NA":1185},{"trials":1167,"activeCount":96},[],{"trials":1169,"activeCount":96},[],{"trials":1171,"activeCount":96},[],{"trials":1173,"activeCount":96},[1174],{"nctId":1175,"briefTitle":1176,"status":162,"phases":1177,"completion":1178,"start":1179,"enrollment":133,"conditions":1180,"interventions":1182},"NCT00360906","Omega-3 Fatty Acid Treatment in Multiple Sclerosis",[86,87],"2008-07","2004-12",[1181],"Relapsing-Remitting Multiple Sclerosis",[1164],{"trials":1184,"activeCount":96},[],{"trials":1186,"activeCount":96},[],{"intervention":1188,"totalTrials":92,"cells":1189},"Ketamine",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1196,"PHASE4":1207,"NA":1209},{"trials":1191,"activeCount":96},[],{"trials":1193,"activeCount":96},[],{"trials":1195,"activeCount":96},[],{"trials":1197,"activeCount":96},[1198],{"nctId":1199,"briefTitle":1200,"status":1201,"phases":1202,"primaryCompletion":338,"completion":338,"start":1203,"enrollment":96,"conditions":1204,"interventions":1206},"NCT01951911","Effectiveness of Ketamine in Malignant Neuropathic Pain Relief","WITHDRAWN",[87],"2013-09",[1205],"Pain, Intractable",[1188],{"trials":1208,"activeCount":96},[],{"trials":1210,"activeCount":96},[],{"intervention":1212,"totalTrials":92,"cells":1213},"folic acid, vitamin B12",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1236,"NA":1238},{"trials":1215,"activeCount":96},[],{"trials":1217,"activeCount":96},[],{"trials":1219,"activeCount":96},[],{"trials":1221,"activeCount":96},[1222],{"nctId":1223,"briefTitle":1224,"status":162,"phases":1225,"primaryCompletion":1226,"completion":1227,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1234},"NCT00354081","WENBIT - Western Norway B Vitamin Intervention Trial",[87],"2007-06","2008-02","1999-04",3096,[1231,1232,1233],"Coronary Artery Disease","Myocardial Infarction","Cerebrovascular Stroke",[1212,1212,1235],"vitamin B6",{"trials":1237,"activeCount":96},[],{"trials":1239,"activeCount":96},[],{"intervention":1235,"totalTrials":92,"cells":1241},{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1248,"PHASE4":1254,"NA":1256},{"trials":1243,"activeCount":96},[],{"trials":1245,"activeCount":96},[],{"trials":1247,"activeCount":96},[],{"trials":1249,"activeCount":96},[1250],{"nctId":1223,"briefTitle":1224,"status":162,"phases":1251,"primaryCompletion":1226,"completion":1227,"start":1228,"enrollment":1229,"conditions":1252,"interventions":1253},[87],[1231,1232,1233],[1212,1212,1235],{"trials":1255,"activeCount":96},[],{"trials":1257,"activeCount":96},[],{"intervention":1259,"totalTrials":92,"cells":1260},"IvIg",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1278,"NA":1280},{"trials":1262,"activeCount":96},[],{"trials":1264,"activeCount":96},[],{"trials":1266,"activeCount":96},[],{"trials":1268,"activeCount":96},[1269],{"nctId":1270,"briefTitle":1271,"status":162,"phases":1272,"completion":1273,"start":1274,"enrollment":350,"conditions":1275,"interventions":1277},"NCT00231439","Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)",[86,87],"2004-07","2003-08",[1276],"Post-Polio Syndrome",[1259],{"trials":1279,"activeCount":96},[],{"trials":1281,"activeCount":96},[],{"intervention":1283,"totalTrials":118,"cells":1284},"Hydrocortisone",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1286,"activeCount":96},[],{"trials":1288,"activeCount":96},[],{"trials":1290,"activeCount":96},[1291,1301],{"nctId":1292,"briefTitle":1293,"status":890,"phases":1294,"primaryCompletion":1295,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1300},"NCT01847690","Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure",[86],"2014-01","2014-03","2013-06",20,[1050],[1283],{"nctId":1302,"briefTitle":1303,"status":890,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1298,"conditions":1307,"interventions":1309},"NCT01771328","Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia",[86],"2017-01","2013-02",[1308],"Adrenal Hyperplasia, Congenital",[1283,1310],"Cortisone acetate",{"trials":1312,"activeCount":96},[],{"trials":1314,"activeCount":96},[],{"trials":1316,"activeCount":96},[],{"intervention":1318,"totalTrials":118,"cells":1319},"Bevacizumab",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1321,"activeCount":96},[],{"trials":1323,"activeCount":96},[],{"trials":1325,"activeCount":96},[1326,1336],{"nctId":1327,"briefTitle":1328,"status":162,"phases":1329,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":1332,"conditions":1333,"interventions":1335},"NCT00139360","Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma",[86],"2011-07","2005-05",35,[1334],"Metastatic Melanoma",[1318],{"nctId":1337,"briefTitle":1338,"status":174,"phases":1339,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":118,"conditions":1342,"interventions":1345},"NCT01705392","Bevacizumab vs Dacarbazine in Metastatic Melanoma",[86],"2017-02-20","2013-01",[1343,1344],"Metastatic Malignant Melanoma","Unresectable Malignant Melanoma",[1318,1346,1347,1348],"Propranolol","Enalapril","Dacarbazine",{"trials":1350,"activeCount":96},[],{"trials":1352,"activeCount":96},[],{"trials":1354,"activeCount":96},[],{"intervention":1356,"totalTrials":92,"cells":1357},"Tetraspan",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1359,"activeCount":96},[],{"trials":1361,"activeCount":96},[],{"trials":1363,"activeCount":96},[1364],{"nctId":1365,"briefTitle":1366,"status":162,"phases":1367,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":350,"conditions":1370,"interventions":1372},"NCT01511120","The Effect on Fluid Balance After Cardiac Surgery After Use of Two Different Priming Protocols",[86],"2013-12","2011-11",[1371],"Coronary Heart Disease",[1356,1373],"acetated Ringer's solution",{"trials":1375,"activeCount":96},[],{"trials":1377,"activeCount":96},[],{"trials":1379,"activeCount":96},[],{"intervention":1373,"totalTrials":92,"cells":1381},{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1383,"activeCount":96},[],{"trials":1385,"activeCount":96},[],{"trials":1387,"activeCount":96},[1388],{"nctId":1365,"briefTitle":1366,"status":162,"phases":1389,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":350,"conditions":1390,"interventions":1391},[86],[1371],[1356,1373],{"trials":1393,"activeCount":96},[],{"trials":1395,"activeCount":96},[],{"trials":1397,"activeCount":96},[],{"intervention":1399,"totalTrials":92,"cells":1400},"Deferasirox",{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1402,"activeCount":96},[],{"trials":1404,"activeCount":96},[],{"trials":1406,"activeCount":96},[1407],{"nctId":1408,"briefTitle":1409,"status":1201,"phases":1410,"primaryCompletion":1305,"completion":1305,"start":1411,"enrollment":96,"conditions":1412,"interventions":1415},"NCT01892644","Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome",[86],"2013-05",[1413,1414],"Hemochromatosis","Myelodysplastic Syndromes",[1399,1399],{"trials":1417,"activeCount":96},[],{"trials":1419,"activeCount":96},[],{"trials":1421,"activeCount":96},[],{"intervention":1423,"totalTrials":92,"cells":1424},"Bortezomib and Temozolomide Phase IB",{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1429,"PHASE3":1443,"PHASE4":1445,"NA":1447},{"trials":1426,"activeCount":96},[],{"trials":1428,"activeCount":96},[],{"trials":1430,"activeCount":96},[1431],{"nctId":1432,"briefTitle":1433,"status":890,"phases":1434,"primaryCompletion":1435,"completion":1436,"start":1437,"enrollment":1438,"conditions":1439,"interventions":1441},"NCT03643549","Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)",[85,86],"2025-06-30","2025-12-31","2018-08-30",63,[1440],"Glioblastoma",[1423,1442],"Bortezomib and Temozolomide Phase II",{"trials":1444,"activeCount":96},[],{"trials":1446,"activeCount":96},[],{"trials":1448,"activeCount":96},[],{"intervention":1442,"totalTrials":92,"cells":1450},{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1452,"activeCount":96},[],{"trials":1454,"activeCount":96},[],{"trials":1456,"activeCount":96},[1457],{"nctId":1432,"briefTitle":1433,"status":890,"phases":1458,"primaryCompletion":1435,"completion":1436,"start":1437,"enrollment":1438,"conditions":1459,"interventions":1460},[85,86],[1440],[1423,1442],{"trials":1462,"activeCount":96},[],{"trials":1464,"activeCount":96},[],{"trials":1466,"activeCount":96},[],{"intervention":1310,"totalTrials":92,"cells":1468},{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1470,"activeCount":96},[],{"trials":1472,"activeCount":96},[],{"trials":1474,"activeCount":96},[1475],{"nctId":1302,"briefTitle":1303,"status":890,"phases":1476,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1298,"conditions":1477,"interventions":1478},[86],[1308],[1283,1310],{"trials":1480,"activeCount":96},[],{"trials":1482,"activeCount":96},[],{"trials":1484,"activeCount":96},[],{"intervention":1486,"totalTrials":92,"cells":1487},"BGB324+pembrolizumab",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1489,"activeCount":96},[],{"trials":1491,"activeCount":96},[],{"trials":1493,"activeCount":96},[1494],{"nctId":1495,"briefTitle":1496,"status":162,"phases":1497,"primaryCompletion":686,"completion":686,"start":1498,"enrollment":1499,"conditions":1500,"interventions":1502},"NCT02872259","BGB324 in Combination With Pembrolizumab or Dabrafenib\u002FTrametinib in Metastatic Melanoma",[85,86],"2017-02-13",74,[1501],"Melanoma",[1486,1503,1504,1505],"BGB324+dabrafenib and trametinib","pembrolizumab","dabrafenib and trametinib",{"trials":1507,"activeCount":96},[],{"trials":1509,"activeCount":96},[],{"trials":1511,"activeCount":96},[],{"intervention":1503,"totalTrials":92,"cells":1513},{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1524,"PHASE4":1526,"NA":1528},{"trials":1515,"activeCount":96},[],{"trials":1517,"activeCount":96},[],{"trials":1519,"activeCount":96},[1520],{"nctId":1495,"briefTitle":1496,"status":162,"phases":1521,"primaryCompletion":686,"completion":686,"start":1498,"enrollment":1499,"conditions":1522,"interventions":1523},[85,86],[1501],[1486,1503,1504,1505],{"trials":1525,"activeCount":96},[],{"trials":1527,"activeCount":96},[],{"trials":1529,"activeCount":96},[],{"intervention":1504,"totalTrials":92,"cells":1531},{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1533,"activeCount":96},[],{"trials":1535,"activeCount":96},[],{"trials":1537,"activeCount":96},[1538],{"nctId":1495,"briefTitle":1496,"status":162,"phases":1539,"primaryCompletion":686,"completion":686,"start":1498,"enrollment":1499,"conditions":1540,"interventions":1541},[85,86],[1501],[1486,1503,1504,1505],{"trials":1543,"activeCount":96},[],{"trials":1545,"activeCount":96},[],{"trials":1547,"activeCount":96},[],{"intervention":1505,"totalTrials":92,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1551,"activeCount":96},[],{"trials":1553,"activeCount":96},[],{"trials":1555,"activeCount":96},[1556],{"nctId":1495,"briefTitle":1496,"status":162,"phases":1557,"primaryCompletion":686,"completion":686,"start":1498,"enrollment":1499,"conditions":1558,"interventions":1559},[85,86],[1501],[1486,1503,1504,1505],{"trials":1561,"activeCount":96},[],{"trials":1563,"activeCount":96},[],{"trials":1565,"activeCount":96},[],{"intervention":1346,"totalTrials":92,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":96},[],{"trials":1571,"activeCount":96},[],{"trials":1573,"activeCount":96},[1574],{"nctId":1337,"briefTitle":1338,"status":174,"phases":1575,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":118,"conditions":1576,"interventions":1577},[86],[1343,1344],[1318,1346,1347,1348],{"trials":1579,"activeCount":96},[],{"trials":1581,"activeCount":96},[],{"trials":1583,"activeCount":96},[],{"intervention":1347,"totalTrials":92,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":96},[],{"trials":1589,"activeCount":96},[],{"trials":1591,"activeCount":96},[1592],{"nctId":1337,"briefTitle":1338,"status":174,"phases":1593,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":118,"conditions":1594,"interventions":1595},[86],[1343,1344],[1318,1346,1347,1348],{"trials":1597,"activeCount":96},[],{"trials":1599,"activeCount":96},[],{"trials":1601,"activeCount":96},[],{"intervention":1348,"totalTrials":92,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1614,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":96},[],{"trials":1607,"activeCount":96},[],{"trials":1609,"activeCount":96},[1610],{"nctId":1337,"briefTitle":1338,"status":174,"phases":1611,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":118,"conditions":1612,"interventions":1613},[86],[1343,1344],[1318,1346,1347,1348],{"trials":1615,"activeCount":96},[],{"trials":1617,"activeCount":96},[],{"trials":1619,"activeCount":96},[],{"intervention":1621,"totalTrials":92,"cells":1622},"Prednisolone",{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1624,"activeCount":96},[],{"trials":1626,"activeCount":96},[],{"trials":1628,"activeCount":96},[1629],{"nctId":1630,"briefTitle":1631,"status":174,"phases":1632,"primaryCompletion":1108,"completion":1108,"start":1633,"enrollment":329,"conditions":1634,"interventions":1639},"NCT03340909","The Norwegian Prednisolone in Early Psychosis Study",[86],"2018-02-02",[1635,1636,1637,1638],"Schizophrenia and Related Disorders","Immune Suppression","Psychosis","Cognitive Change",[1621],{"trials":1641,"activeCount":96},[],{"trials":1643,"activeCount":96},[],{"trials":1645,"activeCount":96},[],{"intervention":1647,"totalTrials":92,"cells":1648},"Ipratropium bromide spray",{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1650,"activeCount":96},[],{"trials":1652,"activeCount":96},[],{"trials":1654,"activeCount":96},[1655],{"nctId":1656,"briefTitle":1657,"status":162,"phases":1658,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1298,"conditions":1661,"interventions":1663},"NCT02755714","Atrovent in Exercise Induced Laryngeal Obstruction (EILO)",[85,86],"2020-10-31","2016-06-22",[1662],"Exercise Induced Laryngeal Obstruction (EILO)",[1647],{"trials":1665,"activeCount":96},[],{"trials":1667,"activeCount":96},[],{"trials":1669,"activeCount":96},[],{"intervention":1671,"totalTrials":92,"cells":1672},"Vaccine Vivotif + Vaccine Dukoral + oats",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1689,"PHASE4":1691,"NA":1693},{"trials":1674,"activeCount":96},[],{"trials":1676,"activeCount":96},[],{"trials":1678,"activeCount":96},[1679],{"nctId":1680,"briefTitle":1681,"status":174,"phases":1682,"primaryCompletion":1683,"completion":177,"start":1684,"enrollment":315,"conditions":1685,"interventions":1687},"NCT00751933","Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis",[86],"2009-10","2008-10",[1686],"Ulcerative Colitis",[1671,1688],"Vaccine Vivotif + Vaccine Dukoral",{"trials":1690,"activeCount":96},[],{"trials":1692,"activeCount":96},[],{"trials":1694,"activeCount":96},[],{"intervention":1688,"totalTrials":92,"cells":1696},{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1707,"PHASE4":1709,"NA":1711},{"trials":1698,"activeCount":96},[],{"trials":1700,"activeCount":96},[],{"trials":1702,"activeCount":96},[1703],{"nctId":1680,"briefTitle":1681,"status":174,"phases":1704,"primaryCompletion":1683,"completion":177,"start":1684,"enrollment":315,"conditions":1705,"interventions":1706},[86],[1686],[1671,1688],{"trials":1708,"activeCount":96},[],{"trials":1710,"activeCount":96},[],{"trials":1712,"activeCount":96},[],{"intervention":1714,"totalTrials":92,"cells":1715},"Everolimus , temozolomide",{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1717,"activeCount":96},[],{"trials":1719,"activeCount":96},[],{"trials":1721,"activeCount":96},[1722],{"nctId":1723,"briefTitle":1724,"status":162,"phases":1725,"primaryCompletion":1726,"completion":1727,"start":1728,"enrollment":1729,"conditions":1730,"interventions":1732},"NCT02248012","Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)",[86],"2018-01","2019-12-01","2014-12",38,[1731],"Neuroendocrine Carcinoma",[1714],{"trials":1734,"activeCount":96},[],{"trials":1736,"activeCount":96},[],{"trials":1738,"activeCount":96},[],{"intervention":1740,"totalTrials":92,"cells":1741},"Etanercept",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1756,"PHASE4":1758,"NA":1760},{"trials":1743,"activeCount":96},[],{"trials":1745,"activeCount":96},[],{"trials":1747,"activeCount":96},[1748],{"nctId":1749,"briefTitle":1750,"status":174,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":23,"conditions":1754,"interventions":1755},"NCT01730495","Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome",[86],"2014-08","2012-10",[168,169],[1740],{"trials":1757,"activeCount":96},[],{"trials":1759,"activeCount":96},[],{"trials":1761,"activeCount":96},[],{"intervention":1763,"totalTrials":92,"cells":1764},"Tetradecylthioacetic acid",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1766,"activeCount":96},[],{"trials":1768,"activeCount":96},[],{"trials":1770,"activeCount":96},[1771],{"nctId":1772,"briefTitle":1773,"status":162,"phases":1774,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1782},"NCT00605787","TTA in Treatment of Diabetes and Dyslipidemia",[86],"2003-06","2007-12","2002-01",16,[1780,1781],"Type 2 Diabetes Mellitus","Dyslipidemia",[1763],{"trials":1784,"activeCount":96},[],{"trials":1786,"activeCount":96},[],{"trials":1788,"activeCount":96},[],{"intervention":1790,"totalTrials":92,"cells":1791},"Sulfasalazine",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1807,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1793,"activeCount":96},[],{"trials":1795,"activeCount":96},[1796],{"nctId":1797,"briefTitle":1798,"status":162,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":1802,"conditions":1803,"interventions":1806},"NCT04205357","Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma",[85],"2022-10-14","2020-03-01",24,[1804,1440,1805],"Glioma","Recurrent Glioblastoma",[1790],{"trials":1808,"activeCount":96},[],{"trials":1810,"activeCount":96},[],{"trials":1812,"activeCount":96},[],{"trials":1814,"activeCount":96},[],{"intervention":1816,"totalTrials":92,"cells":1817},"Gemzar",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1819,"activeCount":96},[],{"trials":1821,"activeCount":96},[1822],{"nctId":1823,"briefTitle":1824,"status":162,"phases":1825,"primaryCompletion":1826,"completion":1826,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1831},"NCT01674556","Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer",[85],"2015-01","2012-02",25,[1830],"Pancreatic Adenocarcinoma",[1816],{"trials":1833,"activeCount":96},[],{"trials":1835,"activeCount":96},[],{"trials":1837,"activeCount":96},[],{"trials":1839,"activeCount":96},[],{"intervention":1841,"totalTrials":92,"cells":1842},"Metformin",{"EARLY_PHASE1":1843,"PHASE1":1858,"PHASE2":1860,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1844,"activeCount":96},[1845],{"nctId":1846,"briefTitle":1847,"status":162,"phases":1848,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1852,"interventions":1854},"NCT03378297","IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC",[84],"2023-01-05","2018-05-04",26,[1853],"Ovarian Cancer",[1841,1855,1856,1857],"Acetylsalicylic acid","Olaparib","Letrozole",{"trials":1859,"activeCount":96},[],{"trials":1861,"activeCount":96},[],{"trials":1863,"activeCount":96},[],{"trials":1865,"activeCount":96},[],{"trials":1867,"activeCount":96},[],{"intervention":1855,"totalTrials":92,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1871,"activeCount":96},[1872],{"nctId":1846,"briefTitle":1847,"status":162,"phases":1873,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1874,"interventions":1875},[84],[1853],[1841,1855,1856,1857],{"trials":1877,"activeCount":96},[],{"trials":1879,"activeCount":96},[],{"trials":1881,"activeCount":96},[],{"trials":1883,"activeCount":96},[],{"trials":1885,"activeCount":96},[],{"intervention":1856,"totalTrials":92,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1889,"activeCount":96},[1890],{"nctId":1846,"briefTitle":1847,"status":162,"phases":1891,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1892,"interventions":1893},[84],[1853],[1841,1855,1856,1857],{"trials":1895,"activeCount":96},[],{"trials":1897,"activeCount":96},[],{"trials":1899,"activeCount":96},[],{"trials":1901,"activeCount":96},[],{"trials":1903,"activeCount":96},[],{"intervention":1857,"totalTrials":92,"cells":1905},{"EARLY_PHASE1":1906,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1907,"activeCount":96},[1908],{"nctId":1846,"briefTitle":1847,"status":162,"phases":1909,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1910,"interventions":1911},[84],[1853],[1841,1855,1856,1857],{"trials":1913,"activeCount":96},[],{"trials":1915,"activeCount":96},[],{"trials":1917,"activeCount":96},[],{"trials":1919,"activeCount":96},[],{"trials":1921,"activeCount":96},[],{"intervention":1923,"totalTrials":92,"cells":1924},"Synachten",{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1926,"activeCount":96},[],{"trials":1928,"activeCount":96},[],{"trials":1930,"activeCount":96},[],{"trials":1932,"activeCount":96},[],{"trials":1934,"activeCount":96},[],{"trials":1936,"activeCount":96},[1937],{"nctId":1938,"briefTitle":1939,"status":162,"phases":1940,"primaryCompletion":1941,"completion":1941,"start":1942,"enrollment":1943,"conditions":1944,"interventions":1946},"NCT02818660","Mass Spectrometry Based Cutoffs for Cortisol After Stimulation Tests",[89],"2017-12-21","2016-05-21",232,[1945],"Adrenal Insufficiency",[1923],{"intervention":1948,"totalTrials":92,"cells":1949},"Epinephrine",{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1956,"PHASE4":1958,"NA":1960},{"trials":1951,"activeCount":96},[],{"trials":1953,"activeCount":96},[],{"trials":1955,"activeCount":96},[],{"trials":1957,"activeCount":96},[],{"trials":1959,"activeCount":96},[],{"trials":1961,"activeCount":96},[1962],{"nctId":1963,"briefTitle":1964,"status":162,"phases":1965,"primaryCompletion":1966,"completion":1967,"start":1968,"enrollment":178,"conditions":1969,"interventions":1970},"NCT03036202","Pharmacokinetics of Epinephrine During Cardiac Arrest",[],"2018-07-12","2018-10-12","2017-06-26",[1157],[1948],{"intervention":1972,"totalTrials":92,"cells":1973},"HyperHAES®",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1980,"PHASE4":1982,"NA":1984},{"trials":1975,"activeCount":96},[],{"trials":1977,"activeCount":96},[],{"trials":1979,"activeCount":96},[],{"trials":1981,"activeCount":96},[],{"trials":1983,"activeCount":96},[],{"trials":1985,"activeCount":96},[1986],{"nctId":1987,"briefTitle":1988,"status":1201,"phases":1989,"enrollment":96,"conditions":1990,"interventions":1994},"NCT01438502","\"The Effect of Reduced Fluid Load After Cardiac Surgery\"",[],[1991,1992,1993],"Fluid Overload","Organ Edema","Organ Function",[1972],{"intervention":1996,"totalTrials":92,"cells":1997},"Storage mite allergen extracts",{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2004,"PHASE4":2006,"NA":2008},{"trials":1999,"activeCount":96},[],{"trials":2001,"activeCount":96},[],{"trials":2003,"activeCount":96},[],{"trials":2005,"activeCount":96},[],{"trials":2007,"activeCount":96},[],{"trials":2009,"activeCount":96},[2010],{"nctId":2011,"briefTitle":2012,"status":162,"phases":2013,"primaryCompletion":2014,"completion":1728,"start":2015,"enrollment":2016,"conditions":2017,"interventions":2019},"NCT01436851","Nasal Provocation Testing in Occupational Rhinitis",[89],"2011-09-01","2010-11-24",17,[2018],"Allergic Rhinitis (Disorder)",[1996],{"intervention":2021,"totalTrials":92,"cells":2022},"Red blood cells",{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":2024,"activeCount":96},[],{"trials":2026,"activeCount":96},[],{"trials":2028,"activeCount":96},[],{"trials":2030,"activeCount":96},[],{"trials":2032,"activeCount":96},[],{"trials":2034,"activeCount":96},[2035],{"nctId":2036,"briefTitle":2037,"status":162,"phases":2038,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":2041,"conditions":2042,"interventions":2044},"NCT02784951","Use of Blood and Plasma in Norwegian Physician-staffed Helicopter Emergency Medical System",[],"2020-12-31","2016-01-01",72,[2043],"Hemorrhagic Shock",[2021,2045,2046],"Whole blood","Freeze dried plasma",{"intervention":2045,"totalTrials":92,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2057,"NA":2059},{"trials":2050,"activeCount":96},[],{"trials":2052,"activeCount":96},[],{"trials":2054,"activeCount":96},[],{"trials":2056,"activeCount":96},[],{"trials":2058,"activeCount":96},[],{"trials":2060,"activeCount":96},[2061],{"nctId":2036,"briefTitle":2037,"status":162,"phases":2062,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":2041,"conditions":2063,"interventions":2064},[],[2043],[2021,2045,2046],{"intervention":2046,"totalTrials":92,"cells":2066},{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2068,"activeCount":96},[],{"trials":2070,"activeCount":96},[],{"trials":2072,"activeCount":96},[],{"trials":2074,"activeCount":96},[],{"trials":2076,"activeCount":96},[],{"trials":2078,"activeCount":96},[2079],{"nctId":2036,"briefTitle":2037,"status":162,"phases":2080,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":2041,"conditions":2081,"interventions":2082},[],[2043],[2021,2045,2046],{"intervention":2084,"totalTrials":92,"cells":2085},"Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine",{"EARLY_PHASE1":2086,"PHASE1":2088,"PHASE2":2090,"PHASE3":2092,"PHASE4":2094,"NA":2096},{"trials":2087,"activeCount":96},[],{"trials":2089,"activeCount":96},[],{"trials":2091,"activeCount":96},[],{"trials":2093,"activeCount":96},[],{"trials":2095,"activeCount":96},[],{"trials":2097,"activeCount":96},[2098],{"nctId":2099,"briefTitle":2100,"status":890,"phases":2101,"primaryCompletion":2102,"completion":2103,"start":2104,"enrollment":2105,"conditions":2106,"interventions":2110},"NCT04060381","Myocardial Deformation Before and After Birth",[],"2023-12","2025-12","2017-04-04",300,[2107,2108,2109],"Myocardial Dysfunction","Newborn Morbidity","Maternal Obesity",[2084],{"intervention":2112,"totalTrials":92,"cells":2113},"Hydroxycobalamin",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2122,"NA":2124},{"trials":2115,"activeCount":96},[],{"trials":2117,"activeCount":96},[],{"trials":2119,"activeCount":96},[],{"trials":2121,"activeCount":96},[],{"trials":2123,"activeCount":96},[],{"trials":2125,"activeCount":96},[2126],{"nctId":2127,"briefTitle":2128,"status":162,"phases":2129,"primaryCompletion":2130,"completion":2131,"start":1179,"enrollment":2132,"conditions":2133,"interventions":2135},"NCT00479479","Cobalamin Supplementation During Infancy; Effect on B-vitamin Status, Growth and Psychomotor Development",[89],"2006-08","2006-12",107,[2134],"Vitamin B 12 Deficiency",[2112],{"intervention":2137,"totalTrials":92,"cells":2138},"Sevelamer",{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2140,"activeCount":96},[],{"trials":2142,"activeCount":96},[],{"trials":2144,"activeCount":96},[],{"trials":2146,"activeCount":96},[],{"trials":2148,"activeCount":96},[],{"trials":2150,"activeCount":96},[2151],{"nctId":2152,"briefTitle":2153,"status":890,"phases":2154,"primaryCompletion":2155,"start":2156,"enrollment":8,"conditions":2157,"interventions":2161},"NCT01057186","Hypophosphatemic Rickets in Norway",[],"2018-12","2009-12",[2158,2159,2160],"Hypophosphatemia, Familial","Rickets","Hyperphosphatemia",[2137]]